|
|
 |
|
Viewing report
|
|
|
|
Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapies
Datamonitor, April 2006, Pages: 50
Mixed Urinary Incontinence (MUI) affects over 10% of women, with women suffering from unpleasant symptoms of both urge urinary incontinence (UUI) and stress urinary incontinence (SUI). At present, no pharmacological agent is able to effectively treat the symptoms of both UUI and SUI.
Scope of this title:
- Quantitative treatment data from 288 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
- Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for MUI
- Influences on treatment choice and perception of current drug therapies including darifenacin, solifenacin and duloxetine
- Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline
Highlights of this title:
Approximately only half of women with MUI seek treatment for their condition. Of these women, less than half receive an accurate diagnosis on first presentation to a physician. Drug manufacturers are therefore failing to maximize revenues. A need for better education of both patients and physicians exists.
With approximately a third of patients most distressed by their SUI symptoms, opportunities still exist for manufacturers with a pharmacological treatment for SUI to establish themselves as physicians first-line treatment option for MUI.
Drug treatment rates are higher in MUI overall than in other urinary incontinence disorders, which may favor this market for novel product launches.
Reasons to order your copy:
- Forecast product sales by understanding key aspects of MUI epidemiology, diagnosis and treatment
- Gain a better understanding of the challenges facing current and future players in the MUI market
- Identify physicians’ key concerns in MUI including unmet needs and the attributes that physicians believe are desirable for future treatments
Customers who bought this item also bought
European Urinary Incontinence Therapeutics Markets
Stress Urinary Incontinence - Opinion Divided on Drug Therapy
Management of Urinary Incontinence and Overactive Bladder - A Global Overview
Urinary Incontinence: Major Milestones
Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
Strategic Perspectives 2002: CNS Disorders in Women - Urinary Incontinence
Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs
Urinary Tract Infections: Growing Resistance Rates bring Opportunities for Both New and Old Drugs
Urinary Incontinence and Overactive Bladder - The Perspective of the Continence Nurse in the US
Trends and Developments in the European Urinary Incontinence
Urinary Incontinence Devices Market: An Analysis
|
|
|
|
